Avalo Therapeutics (AVTX) Interest Coverage Ratio (2014 - 2026)
Avalo Therapeutics (AVTX) posted Interest Coverage Ratio of 0.88 for Q1 2026, up 99.96% on a QoQ basis from 2193.56 in Q4 2025, and up 99.64% year-over-year from 0.44 in Q1 2025.
Avalo Therapeutics (AVTX) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Interest Coverage Ratio history runs 13 years deep, the most recent figure standing at 0.88 for Q1 2026.
- Quarterly Interest Coverage Ratio rose 99.64% year-over-year to 0.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.33 (up 98.46% YoY) and the FY2025 annual result came in at 1.83, down 75.15% from the prior year.
- Interest Coverage Ratio was 0.88 for Q1 2026 at Avalo Therapeutics, up from 2193.56 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 6.84 in Q3 2022 and bottomed at 2193.56 in Q4 2025.
- A 5-year average of 260.64 and a median of 89.1 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 248.12% — and 2024, when it sank 18358.37%.
- Avalo Therapeutics' Interest Coverage Ratio stood at 13.12 in 2022, then soared by 88.37% to 1.53 in 2023, then slumped by 14435.61% to 221.85 in 2024, then sank by 888.76% to 2193.56 in 2025, then soared by 99.96% to 0.88 in 2026.
- Business Quant data shows AVTX's Interest Coverage Ratio at 0.88 in Q1 2026, 2193.56 in Q4 2025, and 325.39 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -0.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.88 |
| Dec 31, 2025 | -2,193.56 |
| Sep 30, 2025 | -325.39 |
| Jun 30, 2025 | -165.09 |
| Mar 31, 2025 | -244.48 |
| Dec 31, 2024 | -221.85 |
| Sep 30, 2024 | -229.66 |
| Jun 30, 2024 | -165.09 |
| Mar 31, 2024 | -595.76 |
| Sep 30, 2023 | -1.53 |
| Jun 30, 2023 | -6.33 |
| Mar 31, 2023 | -3.23 |
| Dec 31, 2022 | -13.12 |
| Sep 30, 2022 | 6.84 |
| Jun 30, 2022 | -3.80 |
| Mar 31, 2022 | -7.27 |
| Dec 31, 2021 | -22.77 |
| Sep 30, 2021 | -4.62 |
| Jun 30, 2021 | -7.79 |
| Mar 31, 2021 | -16.54 |